Jason M. Hafron, director of research at the Michigan Institute of Urology, was taken aback by the results of a study he was conducting: the vast majority of patients with prostate cancer who need regular injections to suppress their testosterone levels didn’t get treated on time.
A curious piece of paper hangs in a frame outside the director’s office at University of Iowa Holden Comprehensive Cancer Center on the second floor of the General Hospital.
